Champions Oncology (CSBR) Gross Margin (2016 - 2025)
Historic Gross Margin for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to 51.7%.
- Champions Oncology's Gross Margin rose 67700.0% to 51.7% in Q4 2025 from the same period last year, while for Oct 2025 it was 50.11%, marking a year-over-year increase of 53700.0%. This contributed to the annual value of 50.15% for FY2025, which is 87700.0% up from last year.
- Champions Oncology's Gross Margin amounted to 51.7% in Q4 2025, which was up 67700.0% from 42.87% recorded in Q3 2025.
- Champions Oncology's Gross Margin's 5-year high stood at 61.17% during Q1 2025, with a 5-year trough of 34.7% in Q1 2024.
- Over the past 5 years, Champions Oncology's median Gross Margin value was 48.05% (recorded in 2022), while the average stood at 47.29%.
- As far as peak fluctuations go, Champions Oncology's Gross Margin tumbled by -117200bps in 2023, and later skyrocketed by 264700bps in 2025.
- Champions Oncology's Gross Margin (Quarter) stood at 52.41% in 2021, then fell by -9bps to 47.88% in 2022, then fell by -11bps to 42.82% in 2023, then grew by 5bps to 44.93% in 2024, then grew by 15bps to 51.7% in 2025.
- Its Gross Margin stands at 51.7% for Q4 2025, versus 42.87% for Q3 2025 and 41.15% for Q2 2025.